Loading…
Employees: 1,344
Size Fulgent Genetics (FLGT) is a United States Health Care company (Medical/Nursing Services) with a market value of $653M, the 2534th largest of 3,117 United States companies the cockpit tracks. Shares closed at $23.74 on 6 Nov 2026.
Performance Over six months the shares gained 48.8%, against -2.1% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 6.8% over the last twelve months (peer median +6.0%); the operating margin is -36.1% (peer median 8.0%).
Valuation It trades at 1.2× enterprise value to sales against a peer median of 1.4× (8th cheapest of 21).
Capital Return on invested capital runs 22.2 points below its cost of capital (9.8% WACC).
Short interest Short interest is 7.8% of the free float (15 Oct 2026).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $324M | $323M | $283M | $289M | $619M |
| Revenue growth | — | +14% | -2% | -53% | — |
| Gross profit | $107M | $123M | $99.2M | $96.6M | $360M |
| EBITDA | -$91.0M | -$67.0M | -$49.0M | -$43.5M | $218M |
| Net income | -$84.4M | -$60.5M | -$42.7M | -$168M | $143M |
| Free cash flow | -$104M | -$124M | -$19.3M | $4.80M | $235M |
| Capital expenditure | $20.1M | $22.6M | $40.3M | $22.2M | $18.8M |
| Total debt | $9.60M | $8.04M | $9.23M | $14.9M | $41.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FLGT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.0% | -4.5% | 5th highest of 21 |
| 6-month return | +48.8% | -2.1% | 2nd highest of 20 |
| Distance from 52-week high | -23.5% | -28.8% | 10th highest of 21 |
| Revenue growth (TTM) | +6.8% | +6.0% | 10th highest of 21 |
| Operating margin | -36.1% | 8.0% | 3rd lowest of 21 |
| EV / Sales | 1.2× | 1.4× | 8th cheapest of 21 |
| ROIC minus cost of capital | -22.2 pp | -1.0 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | 1.2× | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 5.8× | 35.7% | +31.6% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 0.9× | -20.0% | -4.0% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | 2.7× | 8.8% | +3.2% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 0.9× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 1.4× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | 7.7× | n/a | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 2.9× | 18.0% | +12.4% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 8.3× | 27.9% | +10.9% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 1.6× | n/a | n/a |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 1.2× | -4.6% | +5.3% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 0.6× | -9.7% | +1.6% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | 28.2× | n/a | n/a |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 1.5× | 8.3% | +17.7% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | 0.9× | 16.3% | +25.2% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 4.7× | 8.1% | +42.6% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 1.3× | 3.9% | +2.6% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 1.3× | 12.0% | -1.5% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 1.0× | 14.6% | +14.4% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | 6.2× | 22.4% | -5.8% |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 13% | 1.2× | -5.5% | +17.9% |